Healthcare Solutions: Tips for Interstitial Lung Disease Imaging - Health

promotion in Medical Imaging for Interstitial Lung Disease

The collaboration between Serac Healthcare Limited and the University of Exeter has reach a significant milestone with the scanning of the first patient exploitation the novel molecular SPECT imagination agent , technetium-99 m ( Tc-99 m ) maraciclatide . This development is part of the phase II survey entitle ' PRospective Evaluation of Interstitial Lung Disease progression with quantitative CT ( PREDICT - ILD ) . ' The primary aim of this survey is to buttocks the efficacy of quantitative calculate imaging ( Connecticut ) in detection the progression of interstitial lung disease ( ILD).

A bomber - survey has been originate to measure Tc-99 m maraciclatide as an imagination marker for disease omen in a subset of PREDICT - ILD participant . The survey is currently enroll patient across three NHS site in the southwest region of the UK , namely North Bristol NHS Trust ( NBT ) , Royal United Hospitals ( RUH ) NHS Foundation Trust , and Royal Devon University Healthcare NHS Foundation Trust . The carbon_monoxide - head research_worker lead this survey are Professor Chris Scotton , Associate Professor in Respiratory Biomedicine , and Dr. Giles Dixon , Senior Clinical Research Fellow , both from the University of Exeter . PREDICT - ILD is primarily fund by the Wellcome Trust GW4 - CAT HP PhD Programme for Health Professionals.

 Interstital lung disease are a heterogeneous group of over 200 irreversible conditions with change degree of inflammation that lead to scar of the lung . Without treatment , this condition affect over 150,000 people in the UK and consequence in 1 % of death in the country.

Healthcare Solutions: Tips for Interstitial Lung Disease Imaging

The bomber - survey purpose to recruit a sum of 69 participant , with 15 person include in the evaluation of Tc-99 m maraciclatide for disease activity appraisal . This survey will comparison the consumption of the imagination agent between participant with idiopathic pneumonic fibrosis ( IPF ) and not - IPF fibrosing - ILD , as well as healthy control match for age , sexual_activity , and ethnicity . secondary end_point include measure the ability of Tc-99 m maraciclatide to identify v3 activity and predict disease progression in person with fibrosing ILD.

enhance patient result through Precision Medicine

 David Hail , Chief Executive of Serac Healthcare , stress the importance of distinguish between ILD conditions qualify by scar and inflammation to usher allow treatment decision . The development of a molecular imagination marker that can distinguish between early - phase inflammation and fibrosis could significantly impact patient result and facilitate the discovery of new therapies.

Professor Michael Gibbons , Senior Investigator Fellow at the NIHR Exeter Biomedical Research Centre , foreground the potential of early disease progression detection in supply timely entree to disease - modify treatment , represent a significant promotion in pull_off this incurable condition.

The bomber - survey is facilitate by the Nuclear Medicine Department at RUH , Bath , with support from specialist radiologist and ILD doctor . The survey is also back by the University of Exeter 's EPSRC Hub for Quantitative Modelling in Healthcare . Tc-99 m maraciclatide , the investigational imagination agent , show promise in distinguish between inflammation and fibrosis , with deduction for personalize medicine in ILD treatment.

In decision , the ongoing research collaboration between Serac Healthcare and the University of Exeter clasp great potential in advance checkup imagination technology for the detection and omen of interstitial lung disease . With a focus on preciseness medicine and early disease progression detection , this partnership purpose to better patient result and drive the development of effective therapy for ILD.